vs
Intellia Therapeutics, Inc.（NTLA）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
Intellia Therapeutics, Inc.的季度营收约是RIVERVIEW BANCORP INC的1.6倍（$23.0M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -416.2%，领先426.0%），Intellia Therapeutics, Inc.同比增速更快（78.8% vs 10.4%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-69.4M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -10.8%）
Intellia Therapeutics是美国临床阶段生物技术企业，专注于依托CRISPR技术开发具有潜在治愈效果的创新疗法。公司体内项目采用静脉注射CRISPR疗法，通过专属递送技术可在特定靶组织内精准编辑致病基因；体外项目则利用CRISPR改造细胞制备治疗产品，主攻未被满足的医疗需求。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
NTLA vs RVSB — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $14.0M |
| 净利润 | $-95.8M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -428.9% | 12.4% |
| 净利率 | -416.2% | 9.8% |
| 营收同比 | 78.8% | 10.4% |
| 净利润同比 | 25.7% | 11.8% |
| 每股收益（稀释后） | $-0.81 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $23.0M | $14.0M | ||
| Q3 25 | $13.8M | $13.6M | ||
| Q2 25 | $14.2M | $13.3M | ||
| Q1 25 | $16.6M | $12.9M | ||
| Q4 24 | $12.9M | $12.7M | ||
| Q3 24 | $9.1M | $12.8M | ||
| Q2 24 | $7.0M | $12.2M | ||
| Q1 24 | $28.9M | $9.0M |
| Q4 25 | $-95.8M | $1.4M | ||
| Q3 25 | $-101.3M | $1.1M | ||
| Q2 25 | $-101.3M | $1.2M | ||
| Q1 25 | $-114.3M | $1.1M | ||
| Q4 24 | $-128.9M | $1.2M | ||
| Q3 24 | $-135.7M | $1.6M | ||
| Q2 24 | $-147.0M | $966.0K | ||
| Q1 24 | $-107.4M | $-3.0M |
| Q4 25 | -428.9% | 12.4% | ||
| Q3 25 | -808.9% | 10.2% | ||
| Q2 25 | -772.2% | 11.7% | ||
| Q1 25 | -726.6% | 11.3% | ||
| Q4 24 | -1059.9% | 12.4% | ||
| Q3 24 | -1589.0% | 15.5% | ||
| Q2 24 | -1998.6% | 10.0% | ||
| Q1 24 | -394.0% | -47.5% |
| Q4 25 | -416.2% | 9.8% | ||
| Q3 25 | -735.2% | 8.1% | ||
| Q2 25 | -710.8% | 9.2% | ||
| Q1 25 | -687.6% | 8.9% | ||
| Q4 24 | -1001.2% | 9.7% | ||
| Q3 24 | -1489.5% | 12.2% | ||
| Q2 24 | -2112.6% | 7.9% | ||
| Q1 24 | -371.3% | -34.7% |
| Q4 25 | $-0.81 | $0.07 | ||
| Q3 25 | $-0.92 | $0.05 | ||
| Q2 25 | $-0.98 | $0.06 | ||
| Q1 25 | $-1.10 | $0.05 | ||
| Q4 24 | $-1.27 | $0.06 | ||
| Q3 24 | $-1.34 | $0.07 | ||
| Q2 24 | $-1.52 | $0.05 | ||
| Q1 24 | $-1.12 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $449.9M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $671.4M | $164.2M |
| 总资产 | $842.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $449.9M | $28.6M | ||
| Q3 25 | $511.0M | $32.8M | ||
| Q2 25 | $459.7M | $34.2M | ||
| Q1 25 | $503.7M | $29.4M | ||
| Q4 24 | $601.5M | $25.3M | ||
| Q3 24 | $658.1M | $31.0M | ||
| Q2 24 | $691.1M | $27.8M | ||
| Q1 24 | $791.3M | $23.6M |
| Q4 25 | $671.4M | $164.2M | ||
| Q3 25 | $748.4M | $163.5M | ||
| Q2 25 | $715.3M | $162.0M | ||
| Q1 25 | $779.9M | $160.0M | ||
| Q4 24 | $872.0M | $158.3M | ||
| Q3 24 | $962.6M | $160.8M | ||
| Q2 24 | $971.1M | $155.9M | ||
| Q1 24 | $1.0B | $155.6M |
| Q4 25 | $842.1M | $1.5B | ||
| Q3 25 | $925.3M | $1.5B | ||
| Q2 25 | $898.9M | $1.5B | ||
| Q1 25 | $986.2M | $1.5B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $1.2B | $1.5B | ||
| Q2 24 | $1.2B | $1.5B | ||
| Q1 24 | $1.3B | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-69.3M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-69.4M | $-736.0K |
| 自由现金流率自由现金流/营收 | -301.6% | -5.2% |
| 资本支出强度资本支出/营收 | 0.5% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-395.9M | $20.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-69.3M | $-506.0K | ||
| Q3 25 | $-76.9M | $16.8M | ||
| Q2 25 | $-99.6M | $-697.0K | ||
| Q1 25 | $-148.9M | $8.3M | ||
| Q4 24 | $-85.2M | $2.2M | ||
| Q3 24 | $-84.8M | $764.0K | ||
| Q2 24 | $-58.2M | $5.4M | ||
| Q1 24 | $-120.7M | $12.8M |
| Q4 25 | $-69.4M | $-736.0K | ||
| Q3 25 | $-76.9M | $16.4M | ||
| Q2 25 | $-99.9M | $-773.0K | ||
| Q1 25 | $-149.7M | $5.6M | ||
| Q4 24 | $-86.2M | $1.9M | ||
| Q3 24 | $-86.1M | $-1.4M | ||
| Q2 24 | $-59.2M | $5.3M | ||
| Q1 24 | $-123.2M | $7.1M |
| Q4 25 | -301.6% | -5.2% | ||
| Q3 25 | -558.2% | 120.1% | ||
| Q2 25 | -701.0% | -5.8% | ||
| Q1 25 | -900.1% | 43.1% | ||
| Q4 24 | -669.4% | 15.0% | ||
| Q3 24 | -945.2% | -11.3% | ||
| Q2 24 | -850.9% | 43.7% | ||
| Q1 24 | -425.7% | 79.0% |
| Q4 25 | 0.5% | 1.6% | ||
| Q3 25 | 0.2% | 2.9% | ||
| Q2 25 | 1.7% | 0.6% | ||
| Q1 25 | 4.4% | 21.0% | ||
| Q4 24 | 7.6% | 2.4% | ||
| Q3 24 | 14.0% | 17.3% | ||
| Q2 24 | 14.5% | 0.9% | ||
| Q1 24 | 8.7% | 62.0% |
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RVSB
暂无分部数据
